Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia
Status:
Not yet recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
In this study, we tried to demonstrate clinical benefit of additive danazol to romiplostim
therapy in patients with eltrombopag-resistant immune thrombocytopenia
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Kyowa Hakko Kirin Korea Co., Ltd. Kyowa Kirin Korea Co., Ltd.